Quinidine for Pharmacological Cardioversion of Long-lasting Atrial Fibrillation

Overview

Journal J Atr Fibrillation

Date 2017 May 13

PMID 28496695

Citations 1

Authors

Matteo Baroni

Antoine Kheir

Margherita Manfredi

Francesco Pattarino

Flavio Doni

Affiliations

Soon will be listed here.

Abstract

In the daily clinical practice, patients with atrial fibrillation (AF) lasting more than 48h (or not datable at all) are not uncommon. In long-lasting AF changes in electrophysiological features (electrical remodeling) can occur, resulting in a loss of sensibility to most antiarrhythmic drugs. There is strong evidence that the main mechanism involved in electrical remodeling is a global shortening in refractory period. To assess safety and efficacy of quinidine in pharmacological cardioversion of long-lasting AF, compared with propafenone and amiodarone. Ninety consecutive patients with AF lasting more than 6 weeks were randomized to amiodarone (5mg\kg bolus, then 15mg\kg in 24h) , propafenone (2 mg\kg bolus then 0.007mg\kg for 2h), and quinidine (275mg of quinidine arabogalattan sulphate per os every 2h for 8h maximum) for pharmacologic cardioversion. All patients had been previously treated with adequate oral anticoagulation and had been submitted to transthoracic echocardiogram. The 3 groups of patients did not differ for baseline and echocardiographic characteristics. Sinus rhythm was restored in 16 patients treated with quinidine (53%), compared with 6 patients (20%) in the amiodarone and propafenone groups (p<0.01). No major adverse effect was reported during the treatment. Quinidine seems to be safe and effective in pharmacological cardioversion of long-lasting AF.

Citing Articles

External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.

Kukendrarajah K, Ahmad M, Carrington M, Ioannou A, Taylor J, Razvi Y Cochrane Database Syst Rev. 2024; 6:CD013255.

PMID: 38828867 PMC: 11145740. DOI: 10.1002/14651858.CD013255.pub2.

References

Khan I . Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001; 37(2):542-7. DOI: 10.1016/s0735-1097(00)01116-5. View

Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R . Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005; 16(1):54-8. PMC: 1474841. DOI: 10.1046/j.1540-8167.2005.04470.x. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. Rev Port Cardiol. 2007; 26(4):383-446. View

Lafuente-Lafuente C, Mouly S, Longas-Tejero M, Bergmann J . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007; (4):CD005049. DOI: 10.1002/14651858.CD005049.pub2. View

Belhassen B, Glick A, Viskin S . Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol. 2009; 32(3):294-301. DOI: 10.1111/j.1540-8159.2008.02235.x. View

Schwaab B, Katalinic A, Boge U, Loh J, Blank P, Kolzow T . Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients. Ann Noninvasive Electrocardiol. 2009; 14(2):128-36. PMC: 6932034. DOI: 10.1111/j.1542-474X.2009.00287.x. View

SELZER A, WRAY H . QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS. Circulation. 1964; 30:17-26. DOI: 10.1161/01.cir.30.1.17. View

Yang F, Hanon S, Lam P, Schweitzer P . Quinidine revisited. Am J Med. 2009; 122(4):317-21. DOI: 10.1016/j.amjmed.2008.11.019. View

Zehender M, Hohnloser S, Muller B, Meinertz T, Just H . Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992; 19(5):1054-9. DOI: 10.1016/0735-1097(92)90294-w. View

10.

Mehrotra S, Juneja R, Naik N, Pavri B . Successful use of quinine in the treatment of electrical storm in a child with Brugada syndrome. J Cardiovasc Electrophysiol. 2010; 22(5):594-7. DOI: 10.1111/j.1540-8167.2010.01907.x. View

11.

Southworth M, Zarembski D, Viana M, Bauman J . Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. Am J Cardiol. 1999; 83(12):1629-32. DOI: 10.1016/s0002-9149(99)00168-x. View

12.

Khan I, Mehta N, Gowda R . Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003; 89(2-3):239-48. DOI: 10.1016/s0167-5273(02)00477-1. View

13.

Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A . Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs. 2004; 64(24):2741-62. DOI: 10.2165/00003495-200464240-00003. View

14.

Di Benedetto S . Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1997; 80(4):518-9. DOI: 10.1016/s0002-9149(97)00408-6. View

15.

Fetsch T, Bauer P, Engberding R, Koch H, Lukl J, Meinertz T . Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004; 25(16):1385-94. DOI: 10.1016/j.ehj.2004.04.015. View

16.

Coplen S, Antman E, Berlin J, Hewitt P, CHALMERS T . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990; 82(4):1106-16. DOI: 10.1161/01.cir.82.4.1106. View

17.

Kosior D, Kochanowski J, Scislo P, Piatkowski R, Postula M, Rabczenko D . Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. Cardiol J. 2009; 16(6):521-7. View

18.

Allessie M, Ausma J, Schotten U . Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002; 54(2):230-46. DOI: 10.1016/s0008-6363(02)00258-4. View

19.

Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M . Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J. 2004; 25(16):1395-404. DOI: 10.1016/j.ehj.2004.06.014. View

20.

Kerin N, Faitel K, Naini M . The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med. 1996; 156(1):49-53. View